New BARDA contract awards or modifications (size, duration, pricing terms)
International procurement announcements from NATO allies or WHO-affiliated agencies
Outbreak events involving orthopoxviruses (monkeypox, cowpox) driving emergency use demand
US federal budget appropriations for biodefense and pandemic preparedness programs
low - Revenue is driven by government biodefense budgets and geopolitical threat assessments rather than GDP growth or consumer spending. Federal appropriations for pandemic preparedness show minimal correlation to economic cycles, though severe fiscal constraints could impact discretionary defense spending.
Rising rates have moderate negative impact on valuation multiples for this cash-generative, low-growth biodefense stock, as investors discount future contract cash flows more heavily. However, the business itself has minimal interest rate exposure with zero debt and substantial cash reserves ($94M+ based on 9.17x current ratio). Higher rates may marginally increase treasury income on cash holdings.
Single-product dependency on TPOXX creates existential risk if government stockpile strategies shift away from smallpox preparedness or alternative antivirals gain approval
Government budget prioritization risk as biodefense competes with other national security and healthcare spending, particularly during fiscal consolidation periods
Patent expiration risk (key patents expire 2028-2032) could enable generic competition and erode pricing power in government procurement
value - Attracts deep-value and special situations investors focused on cash-generative, asset-light businesses trading below intrinsic value. The 10% FCF yield, 3.3x EV/EBITDA, and zero debt appeal to value-oriented funds, while biodefense contract optionality provides asymmetric upside. Not suitable for growth investors given -0.9% revenue growth and single-product maturity. Event-driven funds may trade around contract announcements and outbreak catalysts.
Trend
-16.3% vs SMA 50 · -38.9% vs SMA 200
Momentum
Volume distribution is neutral or leaning toward distribution. No compelling squeeze setup based on current money flow data.
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
ANALYST ESTIMATES
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2023 | $172.6M $172.6M–$172.6M | — | $1.08 | — | — | Low1 |
FY2024 | $160.2M $160.2M–$160.2M | ▼ -7.2% | $1.05 | ▼ -2.8% | — | Low1 |
FY2025 | $97.5M $97.5M–$97.5M | ▼ -39.1% | $0.67 | ▼ -36.2% | — | Low1 |
Dividend per payment — last 5 periods
INSTITUTIONAL OWNERSHIP
SIGA News
About
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks (biodefense market), vaccines and therapies for emerging infectious diseases, and health preparedness. Its lead product is TPOXX®, also known as tecovirimat and ST-246®, an orally administered and IV formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. TPOXX is a novel small-molecule drug and the US maintains a stockpile of 1.7 million oral courses in the Strategic National Stockpile under Project BioShield. The oral formulation of TPOXX was approved by the FDA for the treatment of smallpox on July 13, 2018. In September 2018, SIGA signed a contract with Biomedical Advanced Research and Development Authority (BARDA) for additional procurement and development related to both oral and intravenous formulations of TPOXX.
| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
SIGA◀ | $4.17 | -2.11% | $299M | 14.7 | -3180.5% | — | 1500 |
| $66.13 | -5.07% | $13.0B | — | +12626.1% | -14525.8% | 1500 | |
| $94.92 | -3.79% | $12.6B | — | +3288.2% | -4239.0% | 1500 | |
| $523.69 | -3.00% | $12.1B | — | +43205.3% | -3008.0% | 1500 | |
| $227.72 | -1.96% | $11.7B | — | +6554.5% | -2868.8% | 1500 | |
| $57.90 | -0.86% | $11.2B | 50.3 | +1459.3% | 147.7% | 1500 | |
| $76.67 | -3.79% | $10.8B | — | +2325815.3% | -19.7% | 1500 | |
| Sector avg | — | -2.94% | — | 32.5 | +341395.5% | -4085.6% | 1500 |